{"id":"experimental-dosing-of-labetalol","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Bronchospasm"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Labetalol's dual mechanism involves non-selective beta-blockade and selective alpha-1 blockade, resulting in reduced peripheral vascular resistance and decreased cardiac output. This combination produces antihypertensive effects with less reflex tachycardia than pure beta-blockers. The experimental dosing referenced likely involves investigation of novel dosing regimens or formulations of this established agent.","oneSentence":"Labetalol is a combined alpha and beta-adrenergic receptor antagonist that reduces blood pressure by blocking both alpha-1 and beta-adrenergic signaling.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:46:09.738Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Hypertensive emergency"}]},"trialDetails":[{"nctId":"NCT03877692","phase":"PHASE4","title":"Acute Control of Chronic Hypertension","status":"TERMINATED","sponsor":"Albany Medical College","startDate":"2019-02-18","conditions":"Preeclampsia With Severe Features, Chronic Hypertension in Obstetric Context","enrollment":10},{"nctId":"NCT03872336","phase":"PHASE4","title":"Acute Labetalol Use in Preeclampsia","status":"TERMINATED","sponsor":"Albany Medical College","startDate":"2019-02-18","conditions":"Preeclampsia With Severe Features","enrollment":15}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":16,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Experimental dosing of labetalol","genericName":"Experimental dosing of labetalol","companyName":"Albany Medical College","companyId":"albany-medical-college","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Labetalol is a combined alpha and beta-adrenergic receptor antagonist that reduces blood pressure by blocking both alpha-1 and beta-adrenergic signaling. Used for Hypertension, Hypertensive emergency.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}